Temozolomide treatment can improve overall survival in aggressive pituitary tumors and pituitary carcinomas.

Date publication

juin 2017

Journal

European journal of endocrinology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr TAILLANDIER Luc

Tous les auteurs :
Lasolle H, Cortet C, Castinetti F, Cloix L, Caron P, Delemer B, Desailloud R, Jublanc C, Lebrun-Frenay C, Sadoul JL, Taillandier L, Batisse-Lignier M, Bonnet F, Bourcigaux N, Bresson D, Chabre O, Chanson P, Garcia C, Haissaguerre M, Reznik Y, Borot S, Villa C, Vasiljevic A, Gaillard S, Jouanneau E, Assié G, Raverot G

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/28432119

Résumé

Only few retrospective studies have reported an efficacy rate of temozolomide (TMZ) in pituitary tumors (PT), all around 50%. However, the long-term survival of treated patients is rarely evaluated. We therefore aimed to describe the use of TMZ on PT in clinical practice and evaluate the long-term survival.

Mots clés

ACTH-Secreting Pituitary Adenoma, drug therapy, Adult, Antineoplastic Agents, Alkylating, therapeutic use, Carcinoma, drug therapy, Chemoradiotherapy, Cohort Studies, Dacarbazine, analogs & derivatives, Drug Resistance, Neoplasm, Female, Follow-Up Studies, France, Humans, Male, Neoplasm Grading, Neoplasm Invasiveness, Neoplasm Recurrence, Local, epidemiology, Pituitary Neoplasms, drug therapy, Practice Patterns, Physicians', Prolactinoma, drug therapy, Retrospective Studies, Survival Analysis, Temozolomide, Tumor Burden, drug effects

Référence

Eur. J. Endocrinol.. 2017 Jun;176(6):769-777